Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari
  • Home
  • Invasive Aspergillosis

Invasive aspergillosis

What is Invasive aspergillosis?

Aspergillosis is caused by Aspergillus spp, a group of pathogenic moulds found in the environment.1,2 Many people inhale Aspergillus spores without experiencing any symptoms, but infection is more likely in those with weakened immune systems.1

Pathogenesis

Aspergillosis is a term used to describe different types of infections, which include chronic pulmonary aspergillosis (in patients with pre-existing lung injury), allergic bronchopulmonary aspergillosis (in patients with asthma and cystic fibrosis) and invasive pulmonary aspergillosis (in patients who are immunocompromised).1,3,4

IA is typically caused by colonisation of the lungs by Aspergillus spp., resulting in invasion of lung tissue by hyphae and subsequent angioinvasion; the infection can then disseminate to other organs, including the central nervous system.3,4

Epidemiology

The global incidence of IA is estimated to be 300,000 cases per year, although this is likely an underestimate due to the difficulties surrounding diagnosis.5 Due to the unspecific nature of symptoms, IA is commonly misdiagnosed in the intensive care unit (ICU).6,7

IA represents a significant contributor to morbidity and mortality in the haemato-oncology setting, the ICU setting and in patients who have undergone transplantation. The case fatality rate is estimated to be close to 90% in high-risk groups, such as bone marrow transplant recipients, and approximately 30% if appropriately managed.2,6,8,9 Factors associated with poor prognosis in patients undergoing transplant include neutropenia and renal or hepatic insufficiency.8

Invasive pulmonary aspergillosis is an emerging co-infection in patients with influenza (influenza-associated pulmonary aspergillosis) and patients with coronavirus disease 2019 (COVID-19-associated pulmonary aspergillosis) who are admitted to the ICU.10 The viral infection and treatments for the viral infection (e.g., corticosteroids) contribute to this risk.11

Risk factors

Known risk factors for IA include:3,4,6,8,12

  • Haematological and oncological malignancies
  • Prolonged neutropenia
  • Use of immunosuppressant drugs, such as corticosteroids
  • Chronic obstructive pulmonary disease
  • Acquired immune deficiency syndrome
  • Liver failure
  • Chronic granulomatous disease
  • Organ transplant recipients
  • Respiratory viral infection, such as influenza or COVID-19

Pathogenic species

  • A. fumigatus is the most common Aspergillus species implicated in IA infection, and represents a major infectious cause of death13
  • Several other Aspergillus species have been implicated in IA, including A. flavus, A. niger, A. terreus, A. versicolor, A. calidoustus and A. nidulans13

References

  1. Latgé JP and Chamilos G. Clin Microbiol Rev. 2019;33:e00140–18.
  2. van de Peppel RJ. Managing invasive aspergillosis: impact on health and personalized prevention or treatment strategies (Doctoral dissertation, Leiden University). 2021.
  3. WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization. Available at: https://www.who.int/publications/i/item/9789240060241. Accessed July 2023.
  4. Kosmidis C and Denning DW. Thorax. 2015;70:270–277.
  5. Bongomin F et al. J Fungi (Basel). 2017;3:57.
  6. Townsend L and Martin-Loeches I. Diagnostics (Basel). 2022;12:2712.
  7. Winters B et al. BMJ Qual Saf. 2012;21:894–902.
  8. Baddley JW et al. Clin Infect Dis. 2010;50:1559–1567.
  9. Lin SJ et al. Clin Infect Dis. 2001;32:358–366.
  10. Verweij P et al. Intensive Care Med. 2020;46:1524–1535.
  11. Hoenigl M et al. Nat Microbiol. 2022;7:1127–1140.
  12. Schauwvlieghe AF et al. Lancet Respir Med. 2018;6:782–792.
  13. Lamoth F. Front Microbiol. 2016;7:683.

SciA-AFN-2400059 | November 2024